Analyst Consensus ?
ConsensusBuy25 ratings
Bullish2184.0%
Neutral416.0%
Bearish00.0%
Bunge Global S.A. · BG · FY2024 Q2 · Calendar Q3 2024
Bunge Raises EPS Guidance as Viterra Progresses and Capex Rises
The quarter supports a constructive operating outlook through higher guidance, improving margins in some regions, and potential scale benefits from Viterra. The case remains dependent on regulatory execution, commodity-margin conditions, and the ability to deploy higher planned capex effectively.
Reported Before market openNYSEConsumer Defensive
$19.83B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.73
Consensus $1.83
EPS surprise
-5.5%
Reported versus consensus
Reported revenue
$13.24B
Consensus $14.30B
Revenue surprise
-7.4%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-8.1%
Event window
SPY move
+1.6%
Same window
Abnormal move
-9.8%
Stock minus SPY
Volume
3.4×
Versus trailing sessions
Subsequent drift
-4.2%
Up to 20 sessions
BGSPY benchmark
Ask FN2 about BG FY2024 Q2
Transcript, numbers and history already loaded
Why did BG fall 8.1% after missing EPS estimates in FY2024 Q2?What changed in BG's guidance and outlook in FY2024 Q2?Give me the bull and bear case for BG after FY2024 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management raised full-year 2024 adjusted EPS guidance to $9.25, reported adjusted EBIT of $519 million, and described Viterra as progressing with several approvals secured while others remain pending. The company also outlined higher 2025 capex, announced the sale of its non-core sugar and bioenergy joint venture to BP, and expanded low-carbon canola and soy-traceability initiatives.
Guidance delta
Full-year 2024 adjusted EPS guidance was raised to $9.25 from the prior quarter's approximately $9.
Key takeaways
- Adjusted EPS was $1.73, below the $1.83 estimate.
- Full-year 2024 adjusted EPS guidance increased to $9.25.
- Viterra approvals are progressing, with some jurisdictions still pending.
- 2025 capex is planned at $1.9-$2.0 billion, above the 2024 plan.
Management priorities
- Complete the Viterra merger and secure remaining regulatory approvals
- Execute multiyear greenfield capex projects
- Scale the low-carbon canola program
- Expand blockchain-based soy traceability
Follow BG with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$103.22Current
$90Low
$126.31Average
$155High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 24, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| JP Morgan | Overweight | Overweight | Maintain | Oct 12, 2026 |
| UBS | Buy | Buy | Maintain | Sep 10, 2026 |
| Barclays | Overweight | Overweight | Maintain | Apr 30, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Mar 11, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Mar 11, 2026 |
| B of A Securities | Buy | Buy | Maintain | Dec 2, 2025 |
| Stephens & Co. | Overweight | Overweight | Maintain | Oct 17, 2025 |
| Citigroup | Neutral | Neutral | Maintain | Apr 15, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Feb 13, 2024 |
| HSBC | Buy | Hold | Upgrade | Feb 9, 2024 |
| Roth MKM | Buy | Buy | Maintain | Feb 5, 2024 |
| Baird | Neutral | Neutral | Maintain | Jan 23, 2024 |
| Wolfe Research | Peer Perform | Outperform | Downgrade | Jan 10, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | Jun 23, 2022 |
| Bank of America | Buy | Neutral | Upgrade | Aug 2, 2016 |
| BB&T Capital | Buy | Buy | Maintain | Jul 12, 2016 |
| Macquarie | Outperform | Outperform | Maintain | Oct 29, 2015 |
| Vertical Research | Buy | Buy | Maintain | Jul 7, 2015 |
| Feltl & Co. | Buy | Hold | Upgrade | Oct 23, 2013 |
| Miller Tabak | Hold | Buy | Downgrade | Oct 21, 2013 |
| PiperJaffray | Overweight | Neutral | Upgrade | Jun 12, 2013 |
| Piper Sandler | Overweight | Neutral | Upgrade | Jun 11, 2013 |
| Topeka | Buy | Hold | Upgrade | Jul 30, 2012 |
| Topeka Capital | Buy | Hold | Upgrade | Jul 29, 2012 |
| Scotiabank | Sector Outperform | Sector Outperform | Maintain | Apr 29, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $103.22. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Manav Gupta | $155 | $123.5 | +50.2% | Sep 10, 2026 |
| UBS | Manav Gupta | $115 | $123.5 | +11.4% | Sep 10, 2026 |
| BMO Capital | Andrew Strelzik | $150 | $113.68 | +45.3% | Aug 13, 2026 |
| Barclays | Analyst unavailable | $150 | $126.31 | +45.3% | Apr 30, 2026 |
| Morgan Stanley | Steven Haynes | $130 | $112.75 | +25.9% | Mar 5, 2026 |
| UBS | Analyst unavailable | $145 | $117.23 | +40.5% | Feb 5, 2026 |
| BMO Capital | Analyst unavailable | $130 | $117.23 | +25.9% | Feb 5, 2026 |
| Stephens | Analyst unavailable | $130 | $117.23 | +25.9% | Feb 5, 2026 |
| Coker Palmer | Thomas Palmer | $117 | $110.06 | +13.4% | Jan 21, 2026 |
| Morgan Stanley | Analyst unavailable | $95 | $97.6 | -8.0% | Oct 27, 2025 |
| Barclays | Benjamin Theurer | $105 | $97.25 | +1.7% | Oct 21, 2025 |
| Stephens | Analyst unavailable | $115 | $95.33 | +11.4% | Oct 17, 2025 |
| BMO Capital | Analyst unavailable | $110 | $93.09 | +6.6% | Oct 16, 2025 |
| Morgan Stanley | Steven Haynes | $83 | $83.14 | -19.6% | Aug 12, 2025 |
| CFRA | Arun Sundaram | $90 | $85.86 | -12.8% | Oct 30, 2024 |
| HSBC | Wesley Brooks | $105 | $104.06 | +1.7% | Apr 25, 2024 |
| Coker Palmer | Thomas Palmer | $122 | $105.79 | +18.2% | Apr 24, 2024 |
| UBS | Analyst unavailable | $133 | $94.47 | +28.9% | Dec 14, 2022 |
| Morgan Stanley | Analyst unavailable | $120 | $115.76 | +16.3% | May 2, 2022 |
| Credit Suisse | Analyst unavailable | $140 | $116.4 | +35.6% | Apr 28, 2022 |
| BMO Capital | Analyst unavailable | $144 | $118.96 | +39.5% | Apr 28, 2022 |
| Barclays | Analyst unavailable | $135 | $115.56 | +30.8% | Apr 25, 2022 |
Track every rating change on BG the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationBunge Global S.A., established in 1818 and headquartered in St. Louis, Missouri, operates as a prominent international agribusiness and food corporation. Its diverse operations are categorized into four main divisions: Agribusiness, Refined and Specialty Oils, Milling, and Sugar and Bioenergy. The Agribusiness segment involves the sourcing, storage, transportation, processing, and sale of agricultural goods and their derivatives. Key commodities include various oilseeds such as soybeans, rapeseed, canola, and sunflower seeds, alongside grains like wheat and corn. These oilseeds are further processed into vegetable oils and protein-rich meals. This segment supplies a wide range of clients, including animal feed and livestock producers, millers of wheat and corn, other oilseed processors, and companies involved in edible oil and biofuel production, catering to both industrial and biodiesel applications.…
Historical context
All BG earningsConsumer Defensive peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| PG The Procter & Gamble Company | FY2027 Q1 · Calendar Q4 2026 | +6.4% | +5.6% | P&G: Volume Growth Supports FY2027 Guidance Despite Cost Headwinds |
Latest beats and misses
Who reports nextBeat on EPS
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
- FCNCOFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- FCNCPFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- RDYFY2027 Q2 · October 23, 2026+24.0% EPS-0.2% move
- SLBFY2026 Q3 · October 23, 2026+3.7% EPS+7.1% move
Missed on EPS
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
Get the BG recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-10-17T05:10:49.140638+00:00
- Polygon adjusted daily market bars · 2026-10-24T20:50:41.894817+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-24T20:50:41.892050+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-24. For educational purposes only; not investment advice.